Teneligliptin as an initial therapy for newly diagnosed, drug naive subjects with type 2 diabetes - Wikidata - wikimedia - TriplyDB

Teneligliptin as an initial therapy for newly diagnosed, drug naive subjects with type 2 diabetes

Teneligliptin as an initial therapy for newly diagnosed, drug naive subjects with type 2 diabetes

http://www.wikidata.org/entity/Q33688333

about

Antidiabetic treatment with gliptins: focus on cardiovascular effects and outcomes Canagliflozin as an Initial Therapy in Drug-Naïve Subjects with Type 2 Diabetes Mellitus: A Potential Involvement of Atherogenic Lipids in its Glycemic Efficacy.The efficacy of vildagliptin concomitant with insulin therapy in type 2 diabetic subjects Teneligliptin, a Dipeptidyl Peptidase-4 Inhibitor, Improves Early-Phase Insulin Secretion in Drug-Naïve Patients with Type 2 Diabetes.Teneligliptin real-world efficacy assessment of type 2 diabetes mellitus patients in India (TREAT-INDIA study)Incretin manipulation in diabetes management.Efficacy and safety of teneligliptin.A Dipeptidyl Peptidase-4 Inhibitor, Teneligliptin, Decreases Plasma Triglyceride-Rich Lipoprotein Remnants in Diabetic Patients with Chronic Kidney Disease Undergoing Hemodialysis.Sodium-glucose Cotransporter-2 Inhibitors: Moving Beyond the Glycemic Treatment Goal.Efficacy and Safety of Teneligliptin in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

P2860

Q26785454-61E45C19-4F41-4519-9149-04E11039BD9E Q33665173-A32F2CA5-3A5B-48F9-ACE2-3051B1424086 Q35166849-FAE38680-165C-4E0F-814B-034AC50C2FDF Q36031120-F4EBE9EF-4304-4D02-867E-3DEA43B5B2AD Q39161794-F30E8899-9FF7-42C5-80D7-BED8557084A4 Q41906284-61B0AC7C-89F5-4E06-A81A-94148F33806A Q42330154-C7D67950-8CE1-4890-8226-18256E74B2A8 Q42370958-8C0AA3B9-E76B-4A1E-B8B1-2FA7D94A4C4D Q47115045-A4119D0B-DDB5-40EB-8ED5-B107607FBFAE Q55340870-1E828DED-A14F-4BBB-8A9B-DCD3FFE55109

P2860

Teneligliptin as an initial therapy for newly diagnosed, drug naive subjects with type 2 diabetes

http://www.wikidata.org/entity/Q33688333

description

2014 nî lūn-bûn

@nan

2014 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Teneligliptin as an initial th ...... subjects with type 2 diabetes

@ast

Teneligliptin as an initial th ...... subjects with type 2 diabetes

@en

type

label

Teneligliptin as an initial th ...... subjects with type 2 diabetes

@ast

Teneligliptin as an initial th ...... subjects with type 2 diabetes

@en

prefLabel

Teneligliptin as an initial th ...... subjects with type 2 diabetes

@ast

Teneligliptin as an initial th ...... subjects with type 2 diabetes

@en

P1433

Q33688333-29AE2113-F80A-4AA0-A93C-BA8F44137D02

P1476

Q33688333-AA3B8303-E4F2-4D3A-BDCE-AB0C035C95DC

P2093

Q33688333-0A0D1F6F-A7D7-44F5-A937-D66CD5038667

Q33688333-AF4338BB-C289-4516-AC0E-8F9A5FA5FD35

Q33688333-EF306ADD-C0C2-401C-9DC9-879580B4A1A4

P2860

Q33688333-044E483E-7980-425E-8BFB-71ABB39C872A

Q33688333-0704BE82-052D-48FC-861F-F74E78E1A105

Q33688333-1639C92F-19F4-4E0A-809D-AF291B0E70CD

Q33688333-196E6F29-B8A5-471B-9441-12BCBDB1DA03

Q33688333-48ACF0BA-DD4A-450B-83EA-FD1654ED62CB

Q33688333-533E02FC-8C96-4F78-BF62-0FDEEB6EBB77

Q33688333-534BB4F8-4985-4828-869B-B47AB808CC11

Q33688333-5355B07E-8BBE-4440-84CA-4AF344536A6D

Q33688333-6818B7F0-1D6E-4A57-95CD-2E0D24B1EA35

Q33688333-6C511B52-30ED-4053-B1AB-574480E040A6

P304

Q33688333-A6A0A870-6F2C-4C5E-B9FA-AD4242CC2F3F

P31

Q33688333-9D1B1418-85AE-4D87-8A2A-7FAC5F60FBAC

P356

Q33688333-0D117C64-935F-4D20-B808-2D4F7A816267

P433

Q33688333-E9B0B702-6194-4E09-B46E-97A5DA1CABA6

P478

Q33688333-61EF56D8-2CCD-4609-B898-D9670014BEA9

P577

Q33688333-974569E4-CB59-43E3-9676-19D8744A0AF5

P5875

Q33688333-5B77B258-5C62-4C88-A99A-E5D1B8CB1C45

P698

Q33688333-E2EBBF24-B8A5-4746-B6A7-28C08A891FB8

P921

Q33688333-AAECD197-50E5-43F3-A172-1DBF4250E476

P932

Q33688333-42B0A66E-AC43-4DE1-80BB-FD8C0F2CDF9B

P356

P1433

Journal of clinical medicine research

P1476

Teneligliptin as an initial th ...... subjects with type 2 diabetes

@en

P2093

Eiji Kutoh

http://www.w3.org/2001/XMLSchema#string

Mitsuru Hirate

http://www.w3.org/2001/XMLSchema#string

Yu Ikeno

http://www.w3.org/2001/XMLSchema#string

P2860

Teneligliptin: a DPP-4 inhibitor for the treatment of type 2 diabetes

Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in man

Discovery and preclinical profile of teneligliptin (3-[(2S,4S)-4-[4-(3-methyl-1-phenyl-1H-pyrazol-5-yl)piperazin-1-yl]pyrrolidin-2-ylcarbonyl]thiazolidine): a highly potent, selective, long-lasting and orally active dipeptidyl peptidase IV inhibitor

A comparative study of the binding modes of recently launched dipeptidyl peptidase IV inhibitors in the active site

Alogliptin as an initial therapy in patients with newly diagnosed, drug naïve type 2 diabetes: a randomized, control trial

DPP-4 inhibitors and lipids: systematic review and meta-analysis.

The national glycohemoglobin standardization program: a five-year progress report.

Sitagliptin phosphate: a DPP-4 inhibitor for the treatment of type 2 diabetes mellitus.

Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors.

A randomized clinical trial comparing low-glycemic index versus ADA dietary education among individuals with type 2 diabetes.

P304

287-294

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.14740/JOCMR1841E

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

6

http://www.w3.org/2001/XMLSchema#string

P577

2014-05-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

262810905

http://www.w3.org/2001/XMLSchema#string

P698

24883155

http://www.w3.org/2001/XMLSchema#string

P921

type-2 diabetes

P932

4039101

http://www.w3.org/2001/XMLSchema#string